Last Updated: September 24, 2026

Details for Patent: 8,377,903


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,377,903
Title:Cladribine regimen for treating multiple sclerosis
Abstract:The present invention is related to the use of Cladribine for the preparation of a pharmaceutical formulation for the treatment of multiple sclerosis, especially relapsing-remitting multiple sclerosis or early secondary progressive multiple sclerosis, wherein the preparation is to be the orally administered and wherein re-treatments are possible.
Inventor(s):Giampiero De luca, Arnaud Ythier, Alain Munafo, Maria Lopez-Bresnahan
Assignee: Merck Serono SA
Application Number:US12/766,173
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,377,903
Patent Claim Types:
see list of patent claims
Use; Formulation; Delivery; Dosage form;

Drugs Protected by US Patent 8,377,903

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,377,903

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
04106909Dec 22, 2004

International Family Members for US Patent 8,377,903

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 1827461 ⤷  Start Trial 122018000021 Germany ⤷  Start Trial
European Patent Office 1827461 ⤷  Start Trial 300930 Netherlands ⤷  Start Trial
European Patent Office 1827461 ⤷  Start Trial CR 2018 00010 Denmark ⤷  Start Trial
European Patent Office 1827461 ⤷  Start Trial 2018C/010 Belgium ⤷  Start Trial
European Patent Office 1827461 ⤷  Start Trial 1890010-0 Sweden ⤷  Start Trial
European Patent Office 1827461 ⤷  Start Trial 9/2018 Austria ⤷  Start Trial
European Patent Office 1827461 ⤷  Start Trial C201830015 Spain ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.